Research brokerage firms on Wall Street are offering a consensus “Buy” rating on shares of Navidea Biopharmaceuticals, Inc. (:NAVB).  Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.00 on the shares.  Based on a recent trade, the shares are hovering around $0.69 which, according to analysts, yield significant upside potential to the $2.00 consensus target price.

When it comes to investing in the equity market, discipline can play a major role in achieving ones goals. A few bad moves can send the investor’s confidence spiraling. Acting purely on emotion can lead to impulsive decisions that may cause the losses to pile up. Creating a solid plan and following through with the plan can help investors stay on track and focus on the proper details. Markets are constantly going up and down and the investing ride can sometimes be a bumpy one. Being able to see the big picture and focus on the important data can help keep the investor tuned in to the right channel. Investors who expect to jump into the market and immediately start raking in the profits may find out fairly quickly that trading without a plan can be a recipe for defeat. 

Although the investing process is fairly straightforward, securing consistent returns in the stock market is not easy. Throwing hard earned money at un-researched investments can eventually lead the investor down the road to ruin. Every individual investor may have different goals when starting out. Aligning these goals with a specific plan can create a solid foundation for the future. Nobody can predict what the future will hold, but being aware of market conditions can be a great asset when attempting to navigate the terrain while mitigating risk. Once the vision of the individual investor is clear, the road to sustaining profits may be much easier to travel.

As company earnings reports continue to roll in, investors will be watching to see which companies hit their numbers for the last reporting period. Investors will also be watching which sectors are reporting the best earnings numbers. A positive overall earnings season could mean that the stock market could keep climbing. Many investors may be cautious with the market trading at current levels. Even though the gloom and doom prognosticators are out in full force, investors have to do the research and decide for themselves which way they believe the market will move in the next couple of months.   

One of the most important factors that investors look at when examining stocks is the consistency of earnings results. When the quarterly earnings report is released, investors watch closely to see if the company is performing up to expectations. A company that fails to meet projections may see large price swings following the report. Of course one bad quarter may not signal trouble, but a company that continually disappoints during earnings season may need to be further examined to help figure out what is going on. Experienced investors will closely watch stock price movements before and after earnings events in order to gain a truer understanding of how the market is reacting to the reports. 

Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will “beat” the artificially lowered estimate in order to get inexperienced investors to buy.

RSI 

Navidea Biopharmaceuticals, Inc. (:NAVB)’s shares may have a significant upside to the consensus target of 2.00, but how has it been performing relative to the market?  The stock’s price is 0.69 and their relative strength index (RSI) stands at 40.80.  RSI is a technical oscillator that shows price strength by comparing upward and downward movements.  It indicates oversold and overbought price levels for a stock.  

Individual investors often strive to create a solid strategy before trying to take on the market. Setting up realistic, attainable goals, may be a good place for the amateur to start. There are many different approaches that the investor can take when getting into the stock market. Some investors will try to follow strategies that have worked for others in the past. Sometimes this will work, and sometimes it will not. Markets and economic landscapes are constantly changing. A strategy that worked yesterday may not work again tomorrow. Investors who put in the time to do the necessary homework may find themselves much better off when the market decides to rear its ugly head at some point down the road.  

Navidea Biopharmaceuticals, Inc. (:NAVB) shares are moving -3.02% trading at $0.69 today.